Please join Cozen O’Connor’s Institutional Response Group (IRG) as we continue our ongoing discussion about practical implementation of the final Title IX regulations.
This two-part set of 90-minute webinars will provide participants with a detailed look at the prescriptive requirements related to live hearings under the final Title IX regulations. They will examine key elements related to questioning by a party’s adviser, determining relevance, limitations on the use of statements not subject to cross-examination, and providing an adviser to conduct questioning at the hearing. The webinars will dive deeply in the language of the preamble to provide insights about implementation of these core provisions. The webinars will also discuss effective practices that balance legal compliance with compassion and care, including how to promote and reinforce decorum, conduct a hearing remotely, and assist the parties – and the decision-makers – to prepare for the hearing. The webinars will also address the structure and format of the live hearing, including the choice of a hearing panel, external adjudicator, or internal administrator; the role of a hearing chair or coordinator; and the necessary procedural steps to ensure the decision-maker is free from bias and conflicts of interest. The webinar will also integrate a discussion of effective practices for the Title IX Coordinator, the decision-maker and the hearing chair/coordinator, including how to apply the standard of evidence to the information in order to reach a determination, evaluating credibility and sanctioning considerations.
These will be the sixth and seventh in a series of webinars hosted by Cozen O’Connor’s Institutional Response Group, a team of dedicated lawyers focusing exclusively on improving institutional responses to sexual and gender-based harassment and violence in the educational context. The series will track the key elements of the Title IX Regulations through the life cycle of a Title IX case from intake through appeal.
Second Date: TBD
CLE is approved in PA, NY, TX, IL, NV, and CA.